Sana Biotechnology updates corporate presentation on SC451 and CAR T programs
Sana Biotechnology said its updated corporate presentation outlines progress toward filing an IND for SC451 this year and advances in its in vivo CAR T fusosome programs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.